Galecto Inc
$ 21.80
1.30%
11 Feb - close price
- Market Cap 43,730,600 USD
- Current Price $ 21.80
- High / Low $ 22.25 / 19.85
- Stock P/E N/A
- Book Value 5.02
- EPS -12.11
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -1.10 %
- 52 Week High 38.33
- 52 Week Low 2.01
About
Galecto, Inc. is a clinical-stage biotechnology firm based in Copenhagen, Denmark, dedicated to advancing innovative therapies for fibrosis, cancer, and inflammation. The company utilizes its proprietary galectin technology platform to target critical biological pathways, aiming to develop unique treatments that could significantly improve patient outcomes. With a robust pipeline of promising drug candidates, Galecto is strategically positioned to influence the biopharmaceutical industry, presenting a compelling investment opportunity for institutional investors seeking cutting-edge therapeutic advancements.
Analyst Target Price
$32.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-11 | 2025-04-28 | 2025-03-19 | 2024-11-01 | 2024-08-05 | 2024-04-29 | 2024-03-08 | 2023-11-06 | 2023-07-31 | 2023-04-28 | 2023-03-09 |
| Reported EPS | -2.3609 | -2.6 | -1.916 | -5 | -3.39 | -0.16 | -0.2 | -0.24 | -0.3 | -0.41 | -0.51 | -0.55 |
| Estimated EPS | None | 0 | None | -2.82 | -3.7 | -0.31 | -0.41 | -0.31 | -0.47 | -0.59 | -0.62 | -0.57 |
| Surprise | 0 | -2.6 | 0 | -2.18 | 0.31 | 0.15 | 0.21 | 0.07 | 0.17 | 0.18 | 0.11 | 0.02 |
| Surprise Percentage | None% | None% | None% | -77.305% | 8.3784% | 48.3871% | 51.2195% | 22.5806% | 36.1702% | 30.5085% | 17.7419% | 3.5088% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GLTO
2026-02-11 22:57:38
Galecto (GLTO) has successfully priced an upsized public offering, raising approximately $295.9 million in net proceeds. This financing, which included the full exercise of an underwriter option, is expected to fund the company's operations into the Phase 3 development of its drug candidate, DMR-001. Despite caution from management regarding capital-use timeline assumptions, the offering strengthens Galecto’s balance sheet and supports its strategic trajectory, with a current analyst rating of Buy and a $31.00 price target.
2026-02-11 21:57:38
Galecto has entered into an underwriting agreement with Jefferies and Leerink Partners for a public offering of 14,473,685 shares of common stock at $19.00 per share, with an additional 2,171,052 shares option fully exercised. The offering is expected to generate approximately $295.9 million in net proceeds, which Galecto plans to use, along with existing cash, to fund operations into Phase 3 development of DMR-001. The agreement was signed on February 10, 2026, and the offering is set to close on February 12, 2026.
2026-02-11 10:59:00
Galecto, Inc. (GLTO) announced the pricing of a public offering of 14.47 million shares at $19.00 per share, aiming to raise approximately $275 million. Following this news, the stock saw a decline, trading down 3.81% at $20.70. The offering is expected to close around February 12, 2026, with underwriters having an option to purchase an additional 2.17 million shares.
2026-02-11 07:57:59
Galecto, Inc. announced the pricing of its underwritten public offering of over 14.4 million shares of common stock at $19.00 per share, aiming to raise approximately $275 million. The biopharmaceutical company, which develops treatments for blood cancers, has granted underwriters an option for additional shares and expects the offering to close around February 12. Despite not being profitable in the last twelve months, Galecto maintains a strong current ratio of 3.73 and is advancing its clinical pipeline, with Leerink Partners initiating coverage with an Outperform rating.
2026-02-11 03:57:59
Galecto, Inc. (NASDAQ: GLTO) has announced the pricing of its underwritten public offering, selling 14,473,685 shares of common stock at $19.00 per share, aiming to raise approximately $275 million before expenses. The company has also granted underwriters an option to purchase an additional 2,171,052 shares. The offering is expected to close around February 12, 2026, with Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities acting as joint book-running managers.
2026-02-11 03:57:59
Galecto (NASDAQ: GLTO) has announced the pricing of an underwritten public offering for 14,473,685 common shares at $19.00 per share, aiming to raise approximately $275 million before fees. The company has also granted underwriters a 30-day option to purchase an additional 2,171,052 shares. This capital raise is intended to further fund Galecto's hematologic oncology pipeline, continuing its strategic shift into treating blood cancers.
